Early detection of prostate cancer through game-changing molecular biomarkers
Dr. Nallasivam Palanisamy, Henry Ford Cancer Institute, discusses his discovery of the first pseudogene-associated recurrent gene fusion in cancer and the potential for this robust biomarker for application beyond prostate cancer